Request Demo
Last update 21 Oct 2025
SHR-7367
Last update 21 Oct 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms SHR 7367, SHR-7367, SHR7367 |
Target |
Action agonists, antagonists |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists), FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with SHR-7367NCT05740202
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of SHR-7367 in Subjects With Advanced Solid Tumors
100 Clinical Results associated with SHR-7367
Login to view more data
100 Translational Medicine associated with SHR-7367
Login to view more data
100 Patents (Medical) associated with SHR-7367
Login to view more data
100 Deals associated with SHR-7367
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | China | 06 Mar 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 06 Mar 2023 | |
| KRAS G12D mutation Solid Tumors | IND Approval | China | 21 Oct 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free